GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

The global Healthcare Contract Manufacturing Market size is projected to be valued at USD 183.7 billion in 2023 and reach USD 347.5 billion by 2030, growing at a CAGR of 9.5% according to a new report ...

Michelle Horn, Country Medical Director, GSK Canada, said: "The combined submission for asthma and CRSwNP marks a significant step toward addressing the unmet needs of patients. Backed by strong ...